T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event - PubMed (original) (raw)
T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event
Greig P Lennon et al. Immunity. 2009.
Abstract
Type 1 diabetes is a T cell-mediated autoimmune disease, characterized by lymphocytic infiltration of the pancreatic islets. It is currently thought that islet antigen specificity is not a requirement for islet entry and that diabetogenic T cells can recruit a heterogeneous bystander T cell population. We tested this assumption directly by generating T cell receptor (TCR) retrogenic mice expressing two different T cell populations. By combining diabetogenic and nondiabetogenic or nonautoantigen-specific T cells, we demonstrate that bystander T cells cannot accumulate in the pancreatic islets. Autoantigen-specific T cells that accumulate in islets, but do not cause diabetes, were also unaffected by the presence of diabetogenic T cells. Additionally, 67% of TCRs cloned from nonobese diabetic (NOD) islet-infiltrating CD4(+) T cells were able to mediate cell-autonomous islet infiltration and/or diabetes when expressed in retrogenic mice. Therefore, islet entry and accumulation appears to be a cell-autonomous and tightly regulated event and is governed by islet antigen specificity.
Figures
Figure 1. Retroviral-Mediated Stem-Cell Gene Transfer
(A) Schematic representation of the TCRα-2A-TCRβ constructs, including the amino acid sequence of the 2A regions of Thosea asigna virus (T2A) and porcine teschovirus-1 (P2A), GSG linker, and insertion point in the MSCV-IRES-GFP vector. Conserved residues are boxed. The arrow indicates the ‘cleavage’ point between the 2A and 2B peptides. (B) Schematic representation of protocol to produce dual TCR retrogenic mice in NOD/SCID recipients. Retroviral-mediated stem cell gene transfer was performed with MSCV-IRES-GFP and MSCV-IRES-YFP constructs into separate populations of NOD/SCID bone marrow. These were then combined and injected, to produce mice with two different populations of T cells.
Figure 2. HEL-specific “Bystander” CD4+ T cells do not accumulate in the pancreas
Double retrogenic mice, with a diabetogenic T cell labeled with YFP and a HEL-specific “bystander” T cell labeled with GFP. Mice were analyzed 4.5–6.5 weeks post transfer, with the bone marrow, spleen, inguinal lymph nodes, pancreatic lymph nodes and pancreatic islets being extracted, processed, cells counted and subjected to flow cytometric analysis. (A) Representative flow cytometric dot plots from B, gated on live and CD4+ T cells. (B) Mice received bone marrow transduced with either 4.1 or 14H4, or both, at a 50:50 ratio, or a 10:90 ratio. One group received 4.1-YFP bone marrow and bone marrow transduced with empty pMIG vector as a control. Top panel; mean (±SEM) percentage of stem cells for each T cell in the bone marrow, as measured by percentage GFP/YFP expression on Lineage−Sca-1+c-kit+ cells (n=10). Middle and bottom panels, mean (±SEM) numbers of each T cell in the spleen (n=9–10), inguinal lymph nodes (I.L.N, n=7–9), pancreatic lymph nodes (P.L.N., n=6–9) and pancreatic islets (ISLETS, n=10), respectively, as calculated from cell counts and the percentage CD4+FP+ live cells. (C) Representative flow cytometric dot plots from D, showing analysis of T cells from 14H4 HEL-specific mice, injected with 10×106 whole splenocytes from 13 week-old NOD mice, two weeks after bone marrow engraftment, and analyzed 4.5–6.5 weeks post-transplant. Plots are gated on live cells and CD4+ cells. (D) Left panels; percentage of stem cells for each T cell in the bone marrow (n=7–10), as measured by percentage GFP expression on Lineage−Sca-1+c-kit+ cells and total numbers of T cells in the spleen. Right panels show the numbers and ratio to the numbers in the spleen for the pancreatic islets (ISLETS) and pancreatic lymph nodes (P.L.N.), respectively (n=5–9). All figures show mean (±SEM) and numbers were calculated from cell counts and the percentage CD4+GFP+Vβ+ live cells for the retrogenic T cells and the percentage CD4+GFP−TCR+ live cells for the NOD T cells.
Figure 3. An autoantigen-specific CD4+ T cell which does not accumulate in the islet, is increased, but not to a significant extent by the presence of a diabetogenic CD4+ T cell
Retrogenic mice, with diabetogenic 4.1 T cells labeled with YFP and PA17.9G7 GAD-specific T cells labeled with GFP, were analyzed 5.5 weeks post-transplant. (A) Representative flow cytometric dot plots from B, showing 4.1 (YFP) and 9G7 (GFP) T cells in the spleen and pancreatic islets. Plots are gated on live cells and CD4+ cells. (B) Top panels; percentage of stem cells for each T cell in the bone marrow, as measured by percentage GFP/YFP expression on Lineage−Sca-1+c-kit+ cells and total numbers of T cells in the spleen (n=3–5). Next three panels, show numbers and ratio to the numbers in the spleen for the pancreatic islets (ISLETS, n=3–5), inguinal lymph nodes (I.L.N., n=3–5) and pancreatic lymph nodes (P.L.N., n=3–5), respectively. All Figures show mean (±SEM) and numbers were calculated from cell counts and the percentage CD4+FP+ live cells.
Figure 4. Expression of an antigen under the control of a rat-insulin promoter (RIP) allows an antigen-specific CD4+ T cell which does not normally accumulate in the islet, to accumulate
NOD.Cg-Prkdc_scid_ Tg(Ins2-GAD2)2Lt/LtJ transgenic mice and NOD/SCID littermate controls were used as recipients, to generate single retrogenic mice, with either PA21.14H4 “bystander” T cells, 10.23 I-A2-specific T cells, PA17.9G7 GAD-specific T cells or PA19.9G11 GAD-specific T cells. Mice were analyzed at 4.5–6.5 weeks post-transplant. (A) Representative flow cytometric dot plots from B, showing T cells in the spleen and pancreatic islets. Plots are gated on live cells. (B) Top four panels; mean (±SEM) numbers of each T cell in the spleen, inguinal lymph nodes (I.L.N.) pancreatic lymph nodes (P.L.N.), and pancreatic islets (ISLETS), respectively, as calculated from cell counts and the percentage CD4+GFP+ live cells (all n=1–5). Third panel, mean (±SEM) ratio of CD4+ T cells in the islets, relative to the numbers in the spleen. Bottom panel: Percentage insulitis, at 6.5 weeks post-transplant (n=3–6).
Figure 5. An autoantigen-specific CD4+ T cell which accumulates in the islet poorly, is increased, but not to a significant extent by the presence of a diabetogenic CD4+ T cell
Retrogenic mice, with diabetogenic 4.1 T cells labeled with YFP and Phogrin18 phogrin-specific T cells labeled with GFP, were analyzed 4.5–6.5 weeks post-transplant. (A) Representative flow cytometric dot plots from B, showing 4.1 (YFP) and Phogrin18 (GFP) T cells in the spleen and pancreatic islets. Plots are gated on live cells and CD4+ cells. (B) Top panels; percentage of stem cells for each T cell in the bone marrow, as measured by percentage GFP/YFP expression on Lineage−Sca-1+c-kit+ cells and total numbers of T cells in the spleen (n=12–15). Next three panels, show numbers and ratio to the numbers in the spleen for the pancreatic islets (ISLETS, n=12–15), inguinal lymph nodes (I.L.N., n=10–15) and pancreatic lymph nodes (P.L.N., n=10–14), respectively. All Figures show mean (±SEM) and numbers were calculated from cell counts and the percentage CD4+FP+ live cells. * p=0.016, t=2.526, 27 d.f., t-test.
Figure 6. An autoantigen-specific CD4+ T cell which accumulates in the islet but does not cause destruction, does not accumulate in higher numbers in the presence of a diabetogenic CD4+ T cell or T cells from whole NOD splenocytes
Retrogenic mice, with diabetogenic 4.1 T cells labeled with YFP and 12-4.4V1 insulin-specific T cells labeled with GFP, were analyzed 4.5–6.5 weeks post-transplant. (A) Representative flow cytometric dot plots from B, showing 4.1 (YFP) and 12-4.4V1 (GFP) T cells in the spleen and pancreatic islets. Plots are gated on live cells and CD4+ cells. (B) Top panels; percentage of stem cells for each T cell in the bone marrow (n=7–8), as measured by percentage GFP/YFP expression on Lineage−Sca-1+c-kit+ cells and total numbers of T cells in the spleen. Next three panels, show numbers and ratio to the numbers in the spleen for the pancreatic islets (ISLETS), inguinal lymph nodes (I.L.N.) and pancreatic lymph nodes (P.L.N.), respectively (n=6–9). All Figures show mean (±SEM) and numbers were calculated from cell counts and the percentage CD4+FP+ live cells. (C) Diabetes incidence. (D) Representative flow cytometric dot plots from E, showing analysis of T cells from 12-4.4V1 Insulin-specific mice, injected with 10×106 whole splenocytes from 13 week-old NOD mice, two weeks after bone marrow engraftment, and analyzed 4.5–6.5 weeks post-transplant. Plots are gated on live cells and CD4+ cells. (E) Left panels; percentage of stem cells for each T cell in the bone marrow (n=7–10), as measured by percentage GFP expression on Lineage−Sca-1+c-kit+ cells and total numbers of T cells in the spleen. Right panels show the numbers and ratio to the numbers in the spleen for the pancreatic islets (ISLETS) and pancreatic lymph nodes (P.L.N.), respectively (n=5–9). All figures show mean (±SEM) and numbers were calculated from cell counts and the percentage CD4+GFP+Vβ+ live cells for the retrogenic T cells and the percentage CD4+GFP−TCR+ live cells for the NOD T cells.
Figure 7. TCRs isolated from NOD islets-infiltrating CD4+ T cells can mediate T cell accumulation in the islets of retrogenic mice
Vα2+Vβ6+ and Vα2+Vβ10+ CD4+ T cells were single-cell sorted from the spleen and islets of a 13 week-old female NOD mouse. The TCR chains were then amplified using a nested RT-PCR, sequenced and cloned into a 2A-linked retroviral vector. Retrogenic mice generated using these vectors, were analyzed 8-10 weeks after engraftment (n=2–11). Shown are numbers of CD4+GFP+ T cells in the spleen (top panel) and pancreatic islets (bottom panel). Plots are gated on live cells. Islet derived clones are indicated by the black bars and the “I” in their name, splenic clones by open bars and the “S” in their name. NY4.1 is included as a control and is indicated by the gray bar. The * indicates that mice in this group were diabetic when analyzed at 8–10 weeks after engraftment. GL25.10I1 T cells induced rapid diabetes, and these mice were analyzed at 5–6 weeks post engraftment.
Comment in
- Is antigen specificity of autoreactive T cells the key to islet entry?
Penaranda C, Bluestone JA. Penaranda C, et al. Immunity. 2009 Oct 16;31(4):534-6. doi: 10.1016/j.immuni.2009.09.006. Immunity. 2009. PMID: 19833083
Similar articles
- Regulation of diabetes development by regulatory T cells in pancreatic islet antigen-specific TCR transgenic nonobese diabetic mice.
Kanagawa O, Militech A, Vaupel BA. Kanagawa O, et al. J Immunol. 2002 Jun 15;168(12):6159-64. doi: 10.4049/jimmunol.168.12.6159. J Immunol. 2002. PMID: 12055228 - Is antigen specificity of autoreactive T cells the key to islet entry?
Penaranda C, Bluestone JA. Penaranda C, et al. Immunity. 2009 Oct 16;31(4):534-6. doi: 10.1016/j.immuni.2009.09.006. Immunity. 2009. PMID: 19833083 - Autoreactive effector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage.
Diz R, Garland A, Vincent BG, Johnson MC, Spidale N, Wang B, Tisch R. Diz R, et al. PLoS One. 2012;7(12):e52054. doi: 10.1371/journal.pone.0052054. Epub 2012 Dec 14. PLoS One. 2012. PMID: 23251685 Free PMC article. - Tolerance to islet autoantigens in type 1 diabetes.
Bach JF, Chatenoud L. Bach JF, et al. Annu Rev Immunol. 2001;19:131-61. doi: 10.1146/annurev.immunol.19.1.131. Annu Rev Immunol. 2001. PMID: 11244033 Review. - Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus.
Yoon JW, Jun HS. Yoon JW, et al. Ann N Y Acad Sci. 2001 Apr;928:200-11. doi: 10.1111/j.1749-6632.2001.tb05650.x. Ann N Y Acad Sci. 2001. PMID: 11795511 Review.
Cited by
- The beta cell-immune cell interface in type 1 diabetes (T1D).
James EA, Joglekar AV, Linnemann AK, Russ HA, Kent SC. James EA, et al. Mol Metab. 2023 Dec;78:101809. doi: 10.1016/j.molmet.2023.101809. Epub 2023 Sep 20. Mol Metab. 2023. PMID: 37734713 Free PMC article. Review. - Variable frequencies of peripheral T-lymphocyte subsets in the diabetes spectrum from type 1 diabetes through latent autoimmune diabetes in adults (LADA) to type 2 diabetes.
Tan T, Xiang Y, Deng C, Cao C, Ren Z, Huang G, Zhou Z. Tan T, et al. Front Immunol. 2022 Aug 24;13:974864. doi: 10.3389/fimmu.2022.974864. eCollection 2022. Front Immunol. 2022. PMID: 36091068 Free PMC article. - Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3.
Grebinoski S, Zhang Q, Cillo AR, Manne S, Xiao H, Brunazzi EA, Tabib T, Cardello C, Lian CG, Murphy GF, Lafyatis R, Wherry EJ, Das J, Workman CJ, Vignali DAA. Grebinoski S, et al. Nat Immunol. 2022 Jun;23(6):868-877. doi: 10.1038/s41590-022-01210-5. Epub 2022 May 26. Nat Immunol. 2022. PMID: 35618829 Free PMC article. - A dormant T-cell population with autoimmune potential exhibits low self-reactivity and infiltrates islets in type 1 diabetes.
Kong Y, Jing Y, Allard D, Scavuzzo MA, Sprouse ML, Borowiak M, Bettini ML, Bettini M. Kong Y, et al. Eur J Immunol. 2022 Jul;52(7):1158-1170. doi: 10.1002/eji.202149690. Epub 2022 Apr 22. Eur J Immunol. 2022. PMID: 35389516 Free PMC article. - Autoreactive T cell receptors with shared germline-like α chains in type 1 diabetes.
Linsley PS, Barahmand-Pour-Whitman F, Balmas E, DeBerg HA, Flynn KJ, Hu AK, Rosasco MG, Chen J, O'Rourke C, Serti E, Gersuk VH, Motwani K, Seay HR, Brusko TM, Kwok WW, Speake C, Greenbaum CJ, Nepom GT, Cerosaletti K. Linsley PS, et al. JCI Insight. 2021 Nov 22;6(22):e151349. doi: 10.1172/jci.insight.151349. JCI Insight. 2021. PMID: 34806648 Free PMC article.
References
- Arnold PY, Burton AR, Vignali DA. Diabetes incidence is unaltered in glutamate decarboxylase 65-specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer. J Immunol. 2004;173:3103–3111. - PubMed
- Arnold PY, La Gruta NL, Miller T, Vignali KM, Adams PS, Woodland DL, Vignali DA. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol. 2002;169:739–749. - PubMed
- Bridgett M, Cetkovic-Cvrlje M, O'Rourke R, Shi Y, Narayanswami S, Lambert J, Ramiya V, Baekkeskov S, Leiter EH. Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic beta-cells. Diabetes. 1998;47:1848–1856. - PubMed
- Burton AR, Vincent E, Arnold PY, Lennon GP, Smeltzer M, Li CS, Haskins K, Hutton J, Tisch RM, Sercarz EE, Santamaria P, Workman CJ, Vignali DA. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes. 2008;57:1321–1330. - PubMed
- Cantagrel A, Lambert N, Alam A. T cell receptor gene in synovial tissues of rheumatoid arthritis. Int Rev Immunol. 1998;17:323–337. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R56 AI072239-01A2/AI/NIAID NIH HHS/United States
- P30 CA021765/CA/NCI NIH HHS/United States
- AI072239/AI/NIAID NIH HHS/United States
- CA-21765/CA/NCI NIH HHS/United States
- R56 AI072239/AI/NIAID NIH HHS/United States
- P30 CA021765-31/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials